Ab­b­Vie shrugs off $134M cash deals, quit­ting a neu­ro R&D pact with Voy­ager Ther­a­peu­tics on vec­tor­ized an­ti­body treat­ments

It’s the end of the road for Voy­ager Ther­a­peu­tics’ col­lab­o­ra­tion with Ab­b­Vie on tau and al­pha-synu­cle­in vec­tor­ized an­ti­body de­vel­op­ment.

In two deals span­ning the last two years, Ab­b­Vie dropped more than $134 mil­lion up­front for Voy­ager’s pre­clin­i­cal R&D of vec­tor­ized an­ti­body treat­ments for dis­eases like Alzheimer’s and Parkin­son’s. But Voy­ager says Ab­b­Vie is walk­ing away now, with­out of­fer­ing an ex­pla­na­tion for why.

Omar Khwa­ja Voy­ager Ther­a­peu­tics

The first deal, penned in 2018, honed in on the po­ten­tial treat­ment of Alzheimer’s and oth­er neu­rode­gen­er­a­tive dis­eases by re­duc­ing tau pathol­o­gy, now a hot spot­light in the wake of nu­mer­ous amy­loid be­ta set­backs. Ab­b­Vie paid Voy­ager $69 mil­lion up­front to de­vel­op vec­tor­ized an­ti­bod­ies di­rect­ed against tau. Cam­bridge, MA-based Voy­ager had the op­por­tu­ni­ty to bag an­oth­er $155 mil­lion in pre­clin­i­cal and Phase I pay­ments, and $895 mil­lion in de­vel­op­ment and reg­u­la­to­ry mile­stones.

The fol­low­ing year, the col­lab­o­ra­tion ex­pand­ed to in­clude vec­tor­ized an­ti­bod­ies di­rect­ed at patho­log­i­cal species of al­pha-synu­cle­in for the treat­ment of Parkin­son’s dis­ease and oth­er synu­cle­inopathies. In that deal, Voy­ager pock­et­ed $65 mil­lion up­front, with the chance to earn an­oth­er $245 mil­lion in pre­clin­i­cal and Phase I pay­ments, $728 mil­lion in de­vel­op­ment and reg­u­la­to­ry mile­stones, and $500 mil­lion in com­mer­cial mile­stones.

Voy­ager’s one-time in­tra­venous in­jec­tions are de­signed to de­liv­er genes across the blood-brain bar­ri­er that en­code for the pro­duc­tion of  ther­a­peu­tic an­ti­bod­ies.

Fol­low­ing Voy­ager’s R&D, Ab­b­Vie had the op­tion to ad­vance one or more can­di­dates to IND-en­abling stud­ies and clin­i­cal de­vel­op­ment. Af­ter Phase I clin­i­cal de­vel­op­ment, the drug mak­er could have li­censed Voy­ager’s an­ti­body pro­grams for fur­ther clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion — though nei­ther pro­gram made it that far.

With the col­lab­o­ra­tion com­ing to an end, Voy­ager has re­gained full clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion rights to the ex­per­i­men­tal drugs de­vel­oped with Ab­b­Vie in the tau pro­gram. And Voy­ager says it’s free to pur­sue an­oth­er part­ner to de­vel­op its vec­tor­ized an­ti­body pro­grams for tau and al­pha-synu­cle­in.

“Through the tau and al­pha-synu­cle­in col­lab­o­ra­tions, we be­lieve we have made con­sid­er­able progress against tar­gets for neu­rode­gen­er­a­tive dis­eases with this nov­el ap­proach, re­in­forc­ing our en­thu­si­asm for its po­ten­tial to de­liv­er ther­a­peu­ti­cal­ly ef­fi­ca­cious lev­els of bi­o­log­ics to the brain and cen­tral ner­vous sys­tem,” said Omar Khwa­ja, Voy­ager’s CMO and head of R&D, in a pre­pared state­ment.

“We be­lieve our con­tin­ued work on dis­cov­ery and de­sign of nov­el AAV cap­sids with sub­stan­tial­ly im­proved blood-brain bar­ri­er pen­e­trance will al­so con­sid­er­ably broad­en the po­ten­tial of AAV-based gene ther­a­py, in­clud­ing vec­tor­ized an­ti­bod­ies or oth­er bi­o­log­ics, for the treat­ment of se­vere neu­ro­log­i­cal dis­eases,” he con­tin­ued.

Voy­ager’s stock $VY­GR fell about 15% to $9.62 af­ter-hours on Mon­day, af­ter the changes were an­nounced.

The com­pa­ny’s most ad­vanced drug in the pipeline is VY-AADC, an AAV-based gene ther­a­py cur­rent­ly en­rolled in a Phase II tri­al to treat Parkin­son’s dis­ease.

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

President Donald Trump (via AP Images)

Signs of an 'Oc­to­ber Vac­cine Sur­prise' alarm ca­reer sci­en­tists

President Donald Trump, who seems intent on announcing a COVID-19 vaccine before Election Day, could legally authorize a vaccine over the objections of experts, officials at the FDA and even vaccine manufacturers, who have pledged not to release any vaccine unless it’s proved safe and effective.

In podcasts, public forums, social media and medical journals, a growing number of prominent health leaders say they fear that Trump — who has repeatedly signaled his desire for the swift approval of a vaccine and his displeasure with perceived delays at the FDA — will take matters into his own hands, running roughshod over the usual regulatory process.

#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

Having worked in parallel for years to move their respective PD-1 inhibitors up to the first-line treatment of gastrointestinal cancers, Merck and Bristol Myers Squibb finally have the data at ESMO for a showdown.

Comparing KEYNOTE-590 and CheckMate-649, of course, comes with the usual caveats. But a side-by-side look at the overall survival numbers also offer some perspective on a new frontier for the reigning checkpoint rivals, both of whom are claiming to have achieved a first.

#ES­MO20: Bris­tol My­ers marks Op­di­vo's sec­ond ad­ju­vant win — eye­ing a stan­dard of care gap

Moving into earlier and earlier treatment lines, Bristol Myers Squibb is reporting that adjuvant treatment with Opdivo has doubled the time that esophageal or gastroesophageal junction cancer patients stay free of disease.

With the CheckMate-577 data at ESMO, CMO Samit Hirawat said, the company believes it can change the treatment paradigm.

While a quarter to 30% of patients typically achieve a complete response following chemoradiation therapy and surgery, the rest do not, said Ronan Kelly of Baylor University Medical Center. The recurrence rate is also high within the first year, Hirawat added.

Clay Siegall (Life Science Washington via YouTube)

#ES­MO20: Seat­tle Ge­net­ics eyes 4th ap­proval with new da­ta in a crowd­ed field

Does Seattle Genetics have another approval on its hands?

The last 12 months, not so great for the world, has been great for Seattle Genetics. The company landed two separate FDA approvals, signed a $4.5 billion deal with Merck and watched antibody-drug conjugates — the technology they spent years developing to broad industry skepticism — emerge suddenly as one of the most popular approaches in oncology. And on Monday at ESMO, the company and their partners at Genmab unveiled the data behind the ADC it hopes will provide its next major FDA approval.

Jonathan Rigby, Immune Regulation group CEO

Im­mune Reg­u­la­tion, tak­ing two clin­i­cal pro­grams to 're­set' the im­mune sys­tem, nets $53M+ Se­ries B

A little under two years after a company rebranding, Immune Regulation is taking an even bigger step toward advancing its goals.

Formerly known as Peptinnovate, the British biotech announced a $53.4 million Series B early Monday morning, helping to further advance two clinical programs in rheumatoid arthritis and asthma. Though those are the two initial indications the company is focusing on, CEO Jonathan Rigby told Endpoints News he hopes the candidates can be applied to a broad swath of autoimmune disorders.

Israel Lowy (Regeneron)

#ES­MO20: 'As good as any PD-1 out there': Re­gen­eron flash­es PD-(L)1 lung can­cer da­ta to ri­val Mer­ck

Regeneron entered the PD-(L)1 game late, so they devised a two-pronged strategy to catch up with Big Pharma rivals: They would push it into cancers where PD-1s had yet been tested, and they would prove that it’s as powerful in the big indications as any other on the market.

They cleared a hurdle on the first goal Friday, showing a 31% response in patients with the rare skin cancer basal cell carcinoma. And with the data they’re rolling out Monday, Regeneron cancer chief Israel Lowy is ready to declare success on the second.

UP­DAT­ED: Two wild weeks for Grail end in $8B Il­lu­mi­na buy­out

Grail’s whirlwind two weeks have ended in the wealthy arms of its former founder and benefactors.

Illumina has shelled out $8 billion to reacquire the closely-watched liquid biopsy startup they spun out just 5 years ago and sold off much of its shares just 3 years ago. The deal comes nearly two weeks after the well-heeled startup filed for a potentially massive IPO — one that was disrupted just a week later when Bloomberg reported that Illumina was in talks to buy their former spinout for up to $8 billion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Anthony Fauci (AP Images)

A press of­fi­cer at An­tho­ny Fau­ci’s NI­AID was un­masked as a hard-right Covid troll. He just re­tired to­day

William B Crews had been a public affairs specialist at the NIH’s National Institute of Allergy and Infectious Diseases.

That ended today when he informed the agency of his decision to retire, after he was identified as the managing editor at RedState, a prominent Trump loyalist website.

Crews’ RedState duties are performed under the alias streiff. While enjoying the benefits of pseudonymity, he disparaged and worked against NIAID with an incendiary level of rhetoric in the midst of a pandemic.